CIM
ALXN

Calvert Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Calvert Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13,382
Closed -$1.64M – 684
2016
Q4 		$1.64M Sell
13,382
-471
-3% -$57.6K 0.06% 313
2016
Q3 		$1.7M Buy
13,853
+1,069
+8% +$138K 0.06% 308
2016
Q2 		$1.49M Buy
12,784
+453
+4% +$64.3K 0.06% 293
2016
Q1 		$1.72M Buy
12,331
+2,280
+23% +$335K 0.08% 243
2015
Q4 		$1.92M Buy
10,051
+1,790
+22% +$313K 0.09% 210
2015
Q3 		$1.29M Buy
8,261
+1,774
+27% +$324K 0.06% 192
2015
Q2 		$1.17M Sell
6,487
-2,739
-30% -$473K 0.05% 222
2015
Q1 		$1.6M Buy
9,226
+1,424
+18% +$258K 0.1% 176
2014
Q4 		$1.44M Buy
7,802
+624
+9% +$116K 0.1% 186
2014
Q3 		$1.19M Buy
7,178
+5,270
+276% +$865K 0.09% 191
2014
Q2 		$298K Hold
1,908
– – 0.02% 299
2014
Q1 		$290K Buy
1,908
+23
+1% +$3.66K 0.02% 295
2013
Q4 		$251K Hold
1,885
– – 0.02% 295
2013
Q3 		$219K Buy
+1,885
New +$207K 0.03% 295

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Calvert Investment Management's ALXN Position: Q1 2017 in Review

Calvert Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 13,382 shares — an estimated $1.64M sold.

Calvert Investment Management first reported a position in ALXN in Q3 2013 and held it in 14 quarters. The position peaked at $1.92M in Q4 2015. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Calvert Investment Management reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Calvert Investment Management sold 13,382 Alexion Pharmaceuticals shares in Q1 2017, an estimated $1.64M.
  • Calvert Investment Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 14 quarters.
  • Calvert Investment Management's Alexion Pharmaceuticals position peaked at $1.92M in Q4 2015.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Calvert Investment Management's 13F filing for Q1 2017.